



### KEY FEATURES



#### High Growth Potential

GNOM enables investors to access high growth potential through companies that are positioned to benefit from further advances in the field of genomic science.



#### Targeted Exposure

GNOM provides access to emerging areas within the Health Care Sector at the intersection of science and technology.



#### ETF Efficiency

In a single trade, GNOM delivers access to dozens of companies with exposure to the genomics theme.

### FUND DETAILS

|                         |                          |
|-------------------------|--------------------------|
| Inception Date          | 04/05/2019               |
| Underlying Index        | Solactive Genomics Index |
| Number of Holdings      | 37                       |
| Assets Under Management | \$20.26 mil              |
| Total Expense Ratio     | 0.68%                    |
| Distribution Frequency  | Semi-Annually            |

### TRADING DETAILS

|                       |           |
|-----------------------|-----------|
| Ticker                | GNOM      |
| CUSIP                 | 37954Y434 |
| Exchange              | NASDAQ    |
| Bloomberg IOPV Ticker | GNOMIV    |
| Index Ticker          | SOLGNOM   |

### PERFORMANCE (%)

|                          | Current Quarter | Year to Date | One Year | Three Year | Cumulative Since Inception |
|--------------------------|-----------------|--------------|----------|------------|----------------------------|
| GNOM at NAV              | 25.34%          | -            | -        | -          | 1.96%                      |
| GNOM at Market Price     | 25.46%          | -            | -        | -          | 4.13%                      |
| Solactive Genomics Index | 25.60%          | -            | -        | -          | 2.48%                      |

### TOP 10 HOLDINGS (%)

Holdings Subject to Change


|                               |       |                            |       |
|-------------------------------|-------|----------------------------|-------|
| Arrowhead Pharmaceuticals Inc | 5.85% | Audentes Therapeutics Inc  | 4.44% |
| Sarepta Therapeutics Inc      | 5.61% | QIAGEN NV                  | 4.39% |
| Alnylam Pharmaceuticals Inc   | 4.70% | uniQure NV                 | 4.23% |
| PTC Therapeutics Inc          | 4.64% | Vertex Pharmaceuticals Inc | 4.21% |
| BioMarin Pharmaceutical Inc   | 4.48% | Agilent Technologies Inc   | 4.16% |

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. High short term performance of the fund is unusual and investors should not expect such performance to be repeated. Returns for periods greater than one year are annualized. Market price returns are based upon the midpoint of the bid/ask spread at the close of the exchange and do not represent the returns you would receive if you traded shares at other times. For performance data current to the most recent month end, please call 1-888-493-8631, or visit [www.globalxetfs.com](http://www.globalxetfs.com).

### INDUSTRY BREAKDOWN (%)



### COUNTRY BREAKDOWN (%)





## DEFINITIONS

### Solactive Genomics Index

The Solactive Genomics Index tracks the companies that generate revenues from Genomics related business. Genomics business operations include the following: (i) gene editing (ii) genomic sequencing (iii) development and testing of genetic medicine/therapies, (iv) computational genomics and genetic diagnostics, and/or (v) biotechnology.

Global X Management Company, LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company, LLC or Mirae Asset Global Investments.

Investing involves risk, including the possible loss of principal. The investable universe of companies in which GNOM may invest may be limited. The Fund invests in securities of companies engaged in Genomics, Healthcare and Biotechnology sectors. These sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles or from social, economic or political instability in other nations. GNOM is non-diversified. The information provided is not intended for trading purposes, and should not be considered investment advice.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Since the Fund's shares typically do not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

***Carefully consider the fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the fund's full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting [globalxetfs.com](http://globalxetfs.com). Please read the prospectus carefully before investing.***